Table 1.
Characteristics of included studies
| Author Year |
Trial | Product | Target | Phase | N | Median age | Prior lines (median) | Penta drug refractory | All-grade infection | Grade ≥3 infection | Grade 5 infections | Treatment discontinuation∗ | Grade ≥ 3 CRS | Grade ≥3 ICANS | Steroids | Tocilizumab | Grade ≥3 neutropenia | Treatment-emergent hypogammaglobulinemia | Median follow-up (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCMA target (monotherapy) | |||||||||||||||||||
| Wong et al, 20227 | CC-93269-MM-001 | Alnuctamab (CC-93269) | BCMA | 1 | 68 | 63 | 4 | 28% | 34% | 9% | 0% | 0% | 0% | 0% | 18% | 12% | 32% | NR | 4.1 |
| D'Souza et al, 20228 | TNB383B.0001 | ABBV-383 | BCMA | 1 | 124 | 68 | 4 | 35% | 41% | 25% | 6% | NR | 2% | 0% | NR | 14% | 34% | NR | 6.8 |
| Topp et al, 20209 | Pacanalotamab (AMG-420) | BCMA | 1 | 42 | 65 | 5 | NR | 33% | 24% | 5% | NR | 2% | 0% | 38% | 2% | NR | NR | 35 | |
| Harrison et al, 202010 | Pavurutamab (AMG-701) | BCMA | 1 | 85 | 64 | 6 | NR | NR | 15% | 2% | 1% | 9% | 0% | 20% | 34% | NR | NR | 1.7 | |
| Bumma et al,11 2022 | LINKER-MM1 | Linvoseltamab (REGN5458) | BCMA | 1/2 | 252 | 66 | 5 | 37% | 54% | 29% | 4% | NR | 1% | 0% | 10% | 17% | 23% | NR | 3.2 |
| Raje et al,12 2022 | MagnetisMM-1 | Elranatamab | BCMA | 1 | 55 | 64 | 5 | NR | NR | 29% | 2% | NR | 0% | NR | NR | 13% | 71% | 75% | 12.0 |
| Bahlis et al,13 2022 | MagnetisMM-3 | Elranatamab | BCMA | 2 | 123 | 69 | 5 | 42% | 67% | 32% | 5% | 6.5% | 0% | 0% | 8% | 22% | 48% | NR | 12.0 |
| Moreau et al,14 2022 | MajesTEC-1 | Teclistamab | BCMA | 1 | 165 | 64 | 5 | 30% | 76% | 45% | 12% | 1% | 1% | 1% | 8% | 36% | 64% | 75% | 14.1 |
| Abdallah et al,15 2022 | HPN217-3001 | HPN217 Trispecific |
BCMA, albumin | 1 | 62 | 70 | 6 | 42% | 45% | 16% | NR | 0% | 0% | 0% | 2% | 6% | 13% | NR | 2.5 |
| BCMA target (combination therapy) | |||||||||||||||||||
| Grosicki et al,16 2022 | MagnetisMM-5 | Elranatamab + daratumumab | BCMA + CD38 | 3 | 34 | 68 | 4 | 15% | NR | NR | 24% | NR | 0% | 0% | NR | NR | 47% | NR | NR |
| Rodriguez-Otero et al,17 2022 | TRIMM-2 | Teclistamab + daratumumab | BCMA + CD38 | 1b | 65 | 67 | 5 | 31% | 68% | 28% | 5% | NR | 0% | 0% | 5% | 32% | 42% | NR | 6.1 |
| Searle et al,31 2022 | MajesTEC-2 | Teclistamab + dara + len | BCMA + CD38 + IMID | 1b | 32 | 63 | 2 | NR | 91% | 38% | 6% | 3% | 0% | 0% | 16% | 41% | 78% | NR | 8.4 |
| Non-BCMA target (monotherapy) | |||||||||||||||||||
| Trudel et al,18 2021 | Cevostamab (BFCR4350A) | FcRH5 | 1 | 161 | 64 | 6 | 68% | 46% | 20% | 0% | NR | 1% | 4% | 20% | 34% | 37% | NR | 6.1 | |
| Carlos-Stella et al,19 2022 | Forimtamig (RG6234) | GPR5CD | 1 | 108 | 63 | 4.5 | 39% | 53% | 24% | 2% | NR | 2% | 3% | 38% | 31% | 13% | NR | 11.6 | |
| Chari et al,20 2022 | MonumenTAL-1 | Talquetamab | GPRC5D | 1/2 | 232 | 64 | 6 | 30% | 66% | 18% | 0% | 0% | 3% | 0% | 7% | 45% | 37% | 77% | 14.9 |
| Non-BCMA target (combination therapy) | |||||||||||||||||||
| van de Donk et al,21 2022 | TRIMM-2 | Talquetamab + Daratumumab | GPRC5D + CD38 | 1b | 58 | 65 | 5 | 29% | 53% | 17% | 2% | NR | 0% | 0% | 3% | 34% | 22% | NR | 4.0 |
NR, not reported; ICANS, immune effector cell–associated neurotoxicity syndrome; CRS, cytokine release syndrome; BCMA, B-cell maturation antigen; IMID, immunomodulatory therapy; dara, daratumumab; lena, lenalidomide.
∗
Treatment discontinuation secondary to infection.